- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06015737
Исследование по изучению эффективности и безопасности анифлолумаба у взрослых с хронической и/или подострой кожной красной волчанкой (LAVENDER)
Многоцентровое рандомизированное двойное слепое плацебо-контролируемое исследование фазы III для оценки эффективности и безопасности анифролумаба у взрослых с хронической и/или подострой кожной красной волчанкой, рефрактерных и/или непереносимых к противомалярийной терапии
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Kogarah, Австралия, 3168
- Research Site
-
Melbourne, Австралия, 3004
- Research Site
-
Mitcham, Австралия, 3132
- Research Site
-
Westmead, Австралия, 2145
- Research Site
-
Woolloongabba, Австралия, 04102
- Research Site
-
-
-
-
-
Graz, Австрия, 8036
- Research Site
-
Innsbruck, Австрия, 6020
- Research Site
-
Linz, Австрия, 4020
- Research Site
-
Vienna, Австрия, 1130
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires, Аргентина, 1221
- Research Site
-
Córdoba, Аргентина, 5000
- Research Site
-
Córdoba, Аргентина, X5004BAL
- Research Site
-
Quilmes, Аргентина, 1878
- Research Site
-
San Miguel, Аргентина, 1663
- Research Site
-
-
-
-
-
Sofia, Болгария, 1784
- Research Site
-
Sofia, Болгария, 1463
- Research Site
-
Sofia, Болгария, 1528
- Research Site
-
-
-
-
-
Belo Horizonte, Бразилия, 30150-221
- Research Site
-
Porto Alegre, Бразилия, 90035903
- Research Site
-
Rio de Janeiro, Бразилия, 22470-220
- Research Site
-
Salvador, Бразилия, 40150-150
- Research Site
-
São Paulo, Бразилия, 05403-000
- Research Site
-
-
-
-
-
Berlin, Германия, 10117
- Research Site
-
Bochum, Германия, 44791
- Research Site
-
Dresden, Германия, 01307
- Research Site
-
Erlangen, Германия, 91054
- Research Site
-
Essen, Германия, 45147
- Research Site
-
Freiburg im Breisgau, Германия, 79104
- Research Site
-
Hanover, Германия, 30625
- Research Site
-
Kiel, Германия, 24105
- Research Site
-
Leipzig, Германия, 04103
- Research Site
-
Mainz, Германия, 55131
- Research Site
-
Marburg, Германия, 35043
- Research Site
-
Regensburg, Германия, 93053
- Research Site
-
Wuppertal, Германия, 42283
- Research Site
-
-
-
-
-
Athens, Греция, 12462
- Research Site
-
Athens, Греция, 16121
- Research Site
-
-
-
-
-
Aarhus, Дания, 641-8510
- Research Site
-
Copenhagen, Дания, 2100
- Research Site
-
-
-
-
-
Barcelona, Испания, 8035
- Research Site
-
Barcelona, Испания, 08025
- Research Site
-
Castellon, Испания, 12004
- Research Site
-
Granada, Испания, 18012
- Research Site
-
L'Hospitalet de Llobregat, Испания, 08907
- Research Site
-
Las Palmas de Gran Canaria, Испания, 35010
- Research Site
-
Madrid, Испания, 28034
- Research Site
-
Madrid, Испания, 28041
- Research Site
-
Madrid, Испания, 28040
- Research Site
-
Madrid, Испания, 28006
- Research Site
-
Majadahonda, Испания, 28222
- Research Site
-
Salamanca, Испания, 37007
- Research Site
-
Seville, Испания, 41014
- Research Site
-
Valencia, Испания, 46014
- Research Site
-
Valencia, Испания, 46017
- Research Site
-
Vigo, Испания, 36200
- Research Site
-
-
-
-
-
Brescia, Италия, 25123
- Research Site
-
Cona, Италия, 44124
- Research Site
-
Florence, Италия, 50121
- Research Site
-
Milan, Италия, 20132
- Research Site
-
Naples, Италия, 80138
- Research Site
-
Reggio Emilia, Италия, 42123
- Research Site
-
Roma, Италия, 00144
- Research Site
-
Rome, Италия, 00168
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Канада, L8N 3Z5
- Research Site
-
Toronto, Ontario, Канада, M5T 2S8
- Research Site
-
-
-
-
-
Changchun, Китай, 130021
- Research Site
-
Changsha, Китай, 410011
- Research Site
-
Chengdu, Китай, 610021
- Research Site
-
Chongqing, Китай, 400016
- Research Site
-
Dongguan, Китай, 523059
- Research Site
-
Guangzhou, Китай, 510120
- Research Site
-
Heilongjiang, Китай, 150086
- Research Site
-
Jinan, Китай, 250022
- Research Site
-
Shanghai, Китай, 200025
- Research Site
-
Shanghai, Китай, 200443
- Research Site
-
Shenzhen, Китай, 518053
- Research Site
-
Shenzhen, Китай, 518020
- Research Site
-
Shenzhen, Китай, 518052
- Research Site
-
Zhuzhou, Китай, 412007
- Research Site
-
Ürümqi, Китай, CN-830004
- Research Site
-
-
-
-
-
Barranquilla, Колумбия, 080020
- Research Site
-
Bogotá, Колумбия, 110221
- Research Site
-
-
-
-
-
Guadalajara, Мексика, 44340
- Research Site
-
Guadalajara, Мексика, 44610
- Research Site
-
Mexico City, Мексика, 07760
- Research Site
-
Veracruz, Мексика, 91910
- Research Site
-
-
-
-
-
Breda, Нидерланды, 4818 CK
- Research Site
-
Rotterdam, Нидерланды, 3015 GD
- Research Site
-
-
-
-
-
Papatoetoe, Новая Зеландия, 2025
- Research Site
-
-
-
-
-
Katowice, Польша, 40-851
- Research Site
-
Kielce, Польша, 25-316
- Research Site
-
Ossy, Польша, 40-027
- Research Site
-
Rzeszów, Польша, 35-055
- Research Site
-
Warsaw, Польша, 02-637
- Research Site
-
-
-
-
-
Braga, Португалия, 4710-243
- Research Site
-
Lisbon, Португалия, 1649-035
- Research Site
-
Porto, Португалия, 4099-001
- Research Site
-
-
-
-
-
Bucharest, Румыния, 020125
- Research Site
-
Iași, Румыния, 700291
- Research Site
-
-
-
-
-
Belgrade, Сербия, 11000
- Research Site
-
Kragujevac, Сербия, 34000
- Research Site
-
-
-
-
-
Košice, Словакия, 04001
- Research Site
-
Piešťany, Словакия, 92101
- Research Site
-
-
-
-
-
Cambridge, Соединенное Королевство, CB2 0QQ
- Research Site
-
Leeds, Соединенное Королевство, LS2 9JT
- Research Site
-
London, Соединенное Королевство, NW1 2PG
- Research Site
-
London, Соединенное Королевство, SE5 9RS
- Research Site
-
London, Соединенное Королевство, SE1 7EH
- Research Site
-
London, Соединенное Королевство, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Соединенное Королевство, NE1 4LP
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Соединенные Штаты, 85028
- Research Site
-
-
California
-
Covina, California, Соединенные Штаты, 91722
- Research Site
-
La Jolla, California, Соединенные Штаты, 92037
- Research Site
-
Los Angeles, California, Соединенные Штаты, 90045
- Research Site
-
Los Angeles, California, Соединенные Штаты, 90089
- Research Site
-
Orange, California, Соединенные Штаты, 92868
- Research Site
-
San Francisco, California, Соединенные Штаты, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Соединенные Штаты, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Соединенные Штаты, 33309
- Research Site
-
Miami, Florida, Соединенные Штаты, 33174
- Research Site
-
Plantation, Florida, Соединенные Штаты, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60637
- Research Site
-
Chicago, Illinois, Соединенные Штаты, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02114
- Research Site
-
Boston, Massachusetts, Соединенные Штаты, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- Research Site
-
Bloomfield Hills, Michigan, Соединенные Штаты, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Соединенные Штаты, 10028
- Research Site
-
Rochester, New York, Соединенные Штаты, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28207
- Research Site
-
Statesville, North Carolina, Соединенные Штаты, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Соединенные Штаты, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Соединенные Штаты, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Соединенные Штаты, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22903
- Research Site
-
Roanoke, Virginia, Соединенные Штаты, 24016
- Research Site
-
-
-
-
-
Bangkok, Таиланд, 10330
- Research Site
-
Bangkok, Таиланд, 10700
- Research Site
-
Hat Yai, Таиланд, 90110
- Research Site
-
Khlong Luang, Таиланд, 12120
- Research Site
-
Khon Kaen, Таиланд, 40002
- Research Site
-
-
-
-
-
Kaohsiung City, Тайвань, 83301
- Research Site
-
Taichung, Тайвань, 404
- Research Site
-
Taipei, Тайвань, 10449
- Research Site
-
-
-
-
-
Cordaleo, Турция (Туркие), 35575
- Research Site
-
Istanbul, Турция (Туркие), 34098
- Research Site
-
Kayseri, Турция (Туркие), 38039
- Research Site
-
Samsun, Турция (Туркие), 55270
- Research Site
-
-
-
-
-
Iloilo City, Филиппины, 5000
- Research Site
-
Lipa, Филиппины, 4217
- Research Site
-
Manila, Филиппины, 1000
- Research Site
-
-
-
-
-
Bois-Guillaume, Франция, 76031
- Research Site
-
Dijon, Франция, 21000
- Research Site
-
Lyon, Франция, 69437
- Research Site
-
Montivilliers, Франция, 76290
- Research Site
-
Nantes, Франция, 44000
- Research Site
-
Paris, Франция, 75010
- Research Site
-
Paris, Франция, 75014
- Research Site
-
Paris, Франция, 75013
- Research Site
-
Paris, Франция, 75970
- Research Site
-
Poitiers, Франция, 86000, FR
- Research Site
-
Toulouse, Франция, 31059
- Research Site
-
-
-
-
-
Osorno, Чили, 200025
- Research Site
-
Santiago, Чили, 7500571
- Research Site
-
Santiago, Чили, 130021
- Research Site
-
-
-
-
-
Cape Town, Южная Африка, 7500
- Research Site
-
Johannesburg, Южная Африка, 2193
- Research Site
-
-
-
-
-
Seoul, Южная Корея, 03080
- Research Site
-
Seoul, Южная Корея, 06591
- Research Site
-
Seoul, Южная Корея, 06973
- Research Site
-
-
-
-
-
Chūōku, Япония, 104-8560
- Research Site
-
Fukuoka, Япония, 812-8582
- Research Site
-
Kanazawa, Япония, 920-8641
- Research Site
-
Kita-gun, Япония, 761-0793
- Research Site
-
Nagoya, Япония, 457-8510
- Research Site
-
Nagoya, Япония, 467-8602
- Research Site
-
Wakayama, Япония, 641-8510
- Research Site
-
Yokohama, Япония, 232-0024
- Research Site
-
tabashi City, Япония, 173-8606
- Research Site
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Плацебо Компаратор: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Временное ограничение: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change from baseline in total CLASI-A score
Временное ограничение: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Временное ограничение: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Временное ограничение: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Временное ограничение: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Временное ограничение: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Временное ограничение: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Временное ограничение: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Временное ограничение: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Временное ограничение: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Временное ограничение: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Временное ограничение: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Временное ограничение: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Временное ограничение: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Временное ограничение: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Временное ограничение: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of participants with adverse events
Временное ограничение: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Соавторы и исследователи
Спонсор
Соавторы
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- D346BC00001
- 2021-003698-70 (Номер EudraCT)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Сроки обмена IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Критерии совместного доступа к IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Совместное использование IPD Поддерживающий тип информации
- STUDY_PROTOCOL
- САП
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .